Socioeconomic and pharmacoepidemiologic data on Cyclooxygenase-2 (COX-2) selective anti-inflammatory drugs;Cyclooxygenase-2 (COX-2) selektive inhibitoren: Soziookonomische und pharmakoepidemiologische aspekte

Zeitschrift fur Rheumatologie

Volumn 59, Issue 2, 2000, Pages 124-127

  Ruof, J ^a   Hulsemann J L ^b  

^a PFIZER INC   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cost effectiveness; Cox 2 inhibition

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; MISOPROSTOL; NABUMETONE; NAPROXEN;

CANADA; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG SELECTIVITY; GASTROINTESTINAL HEMORRHAGE; GERMANY; HUMAN; OUTCOMES RESEARCH; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; RHEUMATOID ARTHRITIS; SOCIOECONOMICS;

EID: 0034028163     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003930050217     Document Type: Conference Paper

References (15)

1. 1. Department of Clinical Epidemiology and Biostatistics, Mc Master University Health Sciences Centre (1984) How to read clinical journals: VII. To understand an economic evaluation (part A&B). Can Med Assoc J 130:1428-1434 und 1542-1549
2. 2. Eckpunkte zur Gesundheitsreform vereinbart zwischen den Arbeitskreisen, Gesundheit' der Fraktionen der SPD und Bündnis 90/Die Grünen und dem Bundesministerium für Gesundheit (1999). f&w 1-6
3. 3. Fries FJ, Miller RS, Spitz WP, Williams AC, Hubert BH, Bloch AD (1989) Toward an Epidemiology of Gastropathy Associated With Nonsteroidal Antiinflammatory Drug Use. Gastroenterology 96 (Suppl 2):647-655
4. 4. Fries FJ (1991) NSAID Gastropathy: The Second Most Deadly Rheumatic Disease? Epidemiology and Risk Appraisal. J Rheumatol 18 (suppl 28):6-10
5. 5. Gabriel S, Tugwell P, O'Brien B, Yelin E, Drummond M, Ruff B, Brooks P, Bombardier C, Boers M (1999) Report of the OMERACT task force on economic evaluation: Outcome Measures in Rheumatology. J Rheumatol 26:203-206
6. 6. Griffin MR, Ray WA, Schaffner W (1988) Nonsteroidal Anti-Inflammatory Drug Use and Death from Peptic Ulcer in Elderly Persons. Ann Intern Med 109:359-363
7. 7. Göttler M, Schneeweiss S, Hasford J (1997) Adverse Drug Reaction Monitoring - Cost and Benefit Considerations. Part II: Cost and Preventability of ADR's Leading to Hospital Admissions. Pharmacoepidemiol and Drug Safety. 6(S3):71-77
8. 8. Maetzel A, Bombardier C (1998) An examination of the cost effectiveness potential of Cyclooxygenase-2 selective antiinflammatory drugs. Arthritis Rheum 41:S248
9. 9. Mühlberger N, Schneeweiss S, Hasford J (1997) Adverse Drug Reaction Monitoring - Cost and Benefit Considerations. Part I: Frequency of ADR,s Leading to Hospital Admissions. Pharmacoepidemiol and Drug Safety 6 (S3):71-77
10. 10. Myllykangas-Luosujärvi R, Kimmo A, Heikki I (1995) Death Attributed to Antirheumatic Medication in a Nationwide Series of 1666 Patients with Rheumatoid Arthritis Who Have Died. J Rheumatol 22:2214-2217
11. 11. Neumann KP, Brecht JG, Schädlich PK (1993) Kostenvergleichsrechnung zur Prävention NSAR-induzierter Gastroduodenopathien mit Misoprostol. Schriftenreihe des IGSF 41:2-50
12. 12. Schneeweiss S, Goettler M, Hasford J (1997) Adverse Drug Events in Hospitalized Patients (letter). JAMA 277: 1351-1352
13. th annual conference of the International Society of Pharmacoepidemiology, Boston
14. 14. Smalley WE, Griffin MR, Fought RL, Ray WA (1996) Excess Costs from Gastrointestinal Disease Associated with Nonsteroidal Anti-Inflammatory Drugs. J Gen Intern Med 11:461-469
15. 15. Walker A (1999) Mündliche Präsentation bei Pfizer European Outcomes Research Meeting, 16./17.6. 1999, Edinburgh, Scotland